SD-169

Overview

SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK , with an IC 50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC 50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > p38 MAPK

Product Information

• Catalog No.: HY-W015445
• CAS No.: 1670-87-7
• Molecular Formula: C9H8N2O
• Molecular Weight: 160.18
• Purity: 99.17%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.08 mg/mL (12.99 mM); Clear solution
• Availability: In-stock

Source

Original product source